Genomics4S

As genomic technologies move from treating disease to selecting future individuals, definitions of disease cease to function exclusively as medical categories and become social decisions about which traits and what kinds of people should exist.

The global AI in clinical trials market, valued at US$1.20 billion in 2023, is projected to grow at a 12.4% annually, reaching US$2.74 billion by 2030. As AI reshapes how patients are identified, matched, and enrolled in clinical research, regulatory frameworks must evolve to address the structural diversity, data flows, and ethical risks embedded in these emerging platforms.

With the advent of AI in healthcare, expertise and experiences accrued in ethics oversight of other controversial fields of biomedical...

Emotion recognition AI may not compromise the integrity of our bodies directly, but it can undermine our personal autonomy and free will.